Revvity is trading 4.6% down at $121.20 after a broad healthcare-sector selloff.
- The XLV ETF was down 2.19% during regular trading.
- Concerns include worsening U.S. health-insurance coverage, potential loss of ACA subsidies, and pressure on healthcare profitability.
- No fresh earnings release or major company-specific event appeared in September 9 morning headlines; Revvityβs scheduled Wells Fargo conference presentation was the main company event.